Catalent Inc ( (CTLT)) has released its Q1 earnings. Here is a breakdown of the information Catalent Inc presented to its investors. Catalent Inc., a leading global contract development and ...

On Monday, Catalent Inc (CTLT) stock saw a decline, ending the day at $58.69 which represents a decrease of $-0.04 or -0.07% from the prior close of $58.73. The stock opened at $58.92 and touched a ...

Catalent (CTLT) delivered earnings and revenue surprises of -218.18% and 5.28%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Catalent's revenue for fiscal first quarter ended Sept. 30 was $1.02 billion, marginally below analysts' estimates of $1.06 ...

Contract drug manufacturer Catalent , which is in the process of being acquired by Novo Holdings, posted a surprise first-quarter loss and revenue below Wall Street estimates on Tuesday.

Catalent (NYSE:CTLT), a contract development and manufacturing organization (CDMO), reported results for Q1 of fiscal 2025 that missed analyst expectations.

Catalent Inc. (CTLT) announced Loss for first quarter that decreased from last year The company's bottom line totaled -$129 million, ...

(CTLT) on Tuesday reported a loss of $129 million in its fiscal first quarter. The Somerset, New Jersey-based company said it had a loss of 71 cents per share. Losses, adjusted for one-time gains and ...

Novo Holdings planned $16.5 billion purchase of Catalent (NYSE:CTLT) is being probed by the European antitrust regulator. The European Commission has set a date of Dec. 6 to decide if its analysis of ...

Jeff Stute, a veteran investment banker with a career spanning three decades at Perella Weinberg Partners and JPMorgan Chase ...

EU antitrust regulators will decide by Dec. 6 whether to clear Novo Holdings' acquisition of contract drug manufacturer ...

Check the time stamp on this data. Updated AI-Generated Signals for Catalent Inc. (CTLT) available here: CTLT.